Qsymia vs Saxenda
Side-by-side comparison of Qsymia (phentermine + topiramate ER) and Saxenda (liraglutide (daily injection)) across efficacy, food restrictions, monthly cost, and Medicare Bridge coverage.
Qsymia
Based on the data below, Qsymia wins on lower cash price ($230/mo vs $1349/mo). Your situation may differ — try the personalized matcher on the homepage or compute your real out-of-pocket with the cost calculator on each medication's detail page.
Qsymia
phentermine + topiramate ER · Vivus LLC
| Field | Qsymia | Saxenda |
|---|---|---|
| Route | tablet · daily | injection · daily |
| Avg weight loss | 7–11% | 5–8% |
| Food restriction | Take in the morning (avoid evening) | No food restriction |
| Cash from | $230/mo | $1349/mo |
| Savings card | — | — |
| Medicare Bridge | Tier 3 | Tier 4 |
| A1c reduction | — | — |
| FDA approved | 2012-07 | 2014-12 |
- RouteQsymiatablet · dailySaxendainjection · daily
- Avg weight lossQsymia7–11%Saxenda5–8%
- Food restrictionQsymiaTake in the morning (avoid evening)SaxendaNo food restriction
- Cash fromQsymia$230/moSaxenda$1349/mo
- Savings cardQsymia—Saxenda—
- Medicare BridgeQsymiaTier 3SaxendaTier 4
- A1c reductionQsymia—Saxenda—
- FDA approvedQsymia2012-07Saxenda2014-12
Pick Qsymia if…
- You can't reliably do a fasting window before meds
- Cash pay matters more than peak weight loss ($230/mo cheaper)
- You're needle-averse
- You want the higher peak efficacy (11% vs 8%)
Pick Saxenda if…
- You can't reliably do a fasting window before meds
Not sure which fits?
The 30-second matcher on the homepage scores every 2026 GLP-1 against your goals + preferences and recommends the best fit.